Evidence map›Paper›PMID 35600392›Full record

ArticleFrontiers in oncology2022

SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer.

Lirui Dai, Yiran Tao, Zimin Shi, Wulong Liang, Weihua Hu, Zhe Xing, Shaolong Zhou, Xuyang Guo, Xudong Fu, Xinjun Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Lirui DaiInstitute of Neuroscience, Zhengzhou University, Zhengzhou, China.
Yiran TaoInstitute of Neuroscience, Zhengzhou University, Zhengzhou, China.
Zimin ShiInstitute of Neuroscience, Zhengzhou University, Zhengzhou, China.
Wulong LiangDepartment of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Weihua HuDepartment of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Zhe XingInstitute of Neuroscience, Zhengzhou University, Zhengzhou, China.
Shaolong ZhouInstitute of Neuroscience, Zhengzhou University, Zhengzhou, China.
Xuyang GuoInstitute of Neuroscience, Zhengzhou University, Zhengzhou, China.
Xudong FuInstitute of Neuroscience, Zhengzhou University, Zhengzhou, China.
Xinjun WangInstitute of Neuroscience, Zhengzhou University, Zhengzhou, China.
Fifth Affiliated Hospital of Zhengzhou University · CNHenan Provincial Center for Disease Control and Prevention · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The suppressor of cytokine signaling (

Indexed as

biomarkerchemotherapygene expression profilinggenetic and epigenetic alterationsimmune-cell infiltrationimmuno-oncologyimmunotherapySOCS3

Identifiers

PMID35600392
PMCPMC9122507
OpenAlexW4228996547

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.